Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Significant Other events in Q4
events in Q4
- The · Enzymatica's partner Sanofi received approval from the
General which enabled the launch of ColdZyme in these markets.
Meeting on · In December, ColdZyme was approved as a "Natural Health
October 18, Product" by the Canadian authorities (Health Canada).
2021, resolved · In December, the Patent Office in Mexico issued a
to approve an preliminary ruling that it intends to grant Enzymatica a
incentive patent for the cod trypsin that is one of the key components
program for in ColdZyme. Final approval is expected to be granted during
CEO Claus the first half of 2022 and the patent will be valid until
Egstrand 2036.
through an · Through the agreement with STADA, in the fourth quarter
employee Enzymatica gained sales to Finland, Poland, the Balkans, the
option plan, a Netherlands, Greece, and to six new markets: Cyprus,
directed issue Moldavia, Azerbaijan, Georgia, Armenia and Mongolia.
of warrants
and a transfer
of warrants.
- On
2021, the
Board of
Directors
reached a
decision on
financial
targets for
the company.
Net sales in
2026 will
amount to at
least SEK 600
million with
an EBIT margin
of at least 28
%.
- No
events were
reported after
the end of the
quarter.Q4 January-December
- Net sales reached SEK 18.7 (42.3) · Net sales reached SEK 57.2
- The result for the period was SEK -10.8 · The result for the period was
- Earnings per share, basic and diluted, · Earnings per share, basic and
- Cash flow from operating activities for · Cash flow from operating
the period totalled SEK -6.1 (-8.2) million. activities for the period
totalled
SEK -35.4 (-10.7) million.
- Net debt totalled SEK -29.0 (
"The pandemic has laid the foundation for changing consumer behaviours that will benefit Enzymatica, and during Q4/2021 we noted that the cold remedy market continued to recover in many of our key markets. Fourth quarter sales and earnings were in line with our expectations and with the favourable trends we now see in the market, we are optimistic about 2022", said Claus Egstrand, CEO.
The full year-end report is available on: www.enzymatica.se/se/investerare/finansiella-rapporter
This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on 17 February 2022.
For more information, please contact:
Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 (0) 708 55 11 85 | Email: stefan.olsson@enzymatica.com
Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se. Enzymatica's Certified Adviser is Erik Penser Bank. Tel: +46 8 463 83 00 Email: certifiedadviser@penser.se.